본 연구는 교근비대의 중요한 기여요인으로 간주되는 이갈이의 영향을 평가하기 위해 이갈이 습관의 유무에 따른 BTX-A 주사후의 임상적 변화를 조사하였다. 실험을 위해 양측성 교근비대를 가진 지원자 중, 야간 이갈이 습관을 가지고 있는 지원자 5명과 이갈이 습관이 없는 지원자 5명을 선택하여 BTX-A(Allergen Inc., $Botox^{(R)}$)를 25 unit씩을 양측 교근에 각각 주사하였다. BTX-A의 교근주사 후에 나타나는 변화를 평가하기 위하여 주사 전과 주사 후 2주, 4주, 8주, 3개월, 6개월 9개월에 각각 검사를 시행하여 초음파를 이용한 전측두근과 교근의 두께 측정, 전치부와 구치부의 최대교합력 측정, 교합력의 변화에 대한 주관적 평가를 비교하였다. 교근에 BTX-A를 주사한 후에 이갈이군과 비이갈이군 모두 초음파검사에서 교근의 두께가 감소되어 3개월 정도에 가장 현저한 위축 소견을 보였으며 이후 점차 회복되어가는 양상을 보였다(p<0.001). 비이갈이군과 비교하였을 때 이갈이군에서 교근두께의 회복이 더 현저하였으나, 주사 후 9개월에도 치료전과 비교했을 때는 여전히 근위축이 관찰되었다. 구치부 최대교합력도 교근두께 변화와 유사한 양상을 보였다. 전측두근과 전치부 최대 교합력은 주사 후 시간경과에 따른 변화를 보여 주지 않았다(p>0.05). 피검자가 스스로 느끼는 교합력은 주사 2주 후에 가장 저하되었다가 점차 빠르게 회복되어 6개월에서 9개월 사이 이전의 상태로 회복한 반면 교합력측 정기로 측정한 구치부 최대교합력의 상대적 변화는 최대교합력이 원래의 상태로 회복되지 못했음을 보여주었다. BTX-A 주사로 인한 상대적인 구치부 최대교합력의 저하는 비이갈이군에서 더욱 현저하게 관찰되었다. 이 실험의 결과는 이갈이는 BTX-A 주사 후에 발생한 교근 위축과 교합력 감소가 원상태로 회복되는 과정에 영향을 미칠 수 있음을 보여준다. 그러므로 이갈이 등의 이상기능 습관을 가진 교근비대 환자의 BTX-A 주사효과를 보다 오래 유지하기 위해서 주사와 함께 습관조절을 위한 교합장치의 사용을 고려할 필요가 있을 것으로 생각된다.
본 연구는 교근비대의 중요한 기여요인으로 간주되는 이갈이의 영향을 평가하기 위해 이갈이 습관의 유무에 따른 BTX-A 주사후의 임상적 변화를 조사하였다. 실험을 위해 양측성 교근비대를 가진 지원자 중, 야간 이갈이 습관을 가지고 있는 지원자 5명과 이갈이 습관이 없는 지원자 5명을 선택하여 BTX-A(Allergen Inc., $Botox^{(R)}$)를 25 unit씩을 양측 교근에 각각 주사하였다. BTX-A의 교근주사 후에 나타나는 변화를 평가하기 위하여 주사 전과 주사 후 2주, 4주, 8주, 3개월, 6개월 9개월에 각각 검사를 시행하여 초음파를 이용한 전측두근과 교근의 두께 측정, 전치부와 구치부의 최대교합력 측정, 교합력의 변화에 대한 주관적 평가를 비교하였다. 교근에 BTX-A를 주사한 후에 이갈이군과 비이갈이군 모두 초음파검사에서 교근의 두께가 감소되어 3개월 정도에 가장 현저한 위축 소견을 보였으며 이후 점차 회복되어가는 양상을 보였다(p<0.001). 비이갈이군과 비교하였을 때 이갈이군에서 교근두께의 회복이 더 현저하였으나, 주사 후 9개월에도 치료전과 비교했을 때는 여전히 근위축이 관찰되었다. 구치부 최대교합력도 교근두께 변화와 유사한 양상을 보였다. 전측두근과 전치부 최대 교합력은 주사 후 시간경과에 따른 변화를 보여 주지 않았다(p>0.05). 피검자가 스스로 느끼는 교합력은 주사 2주 후에 가장 저하되었다가 점차 빠르게 회복되어 6개월에서 9개월 사이 이전의 상태로 회복한 반면 교합력측 정기로 측정한 구치부 최대교합력의 상대적 변화는 최대교합력이 원래의 상태로 회복되지 못했음을 보여주었다. BTX-A 주사로 인한 상대적인 구치부 최대교합력의 저하는 비이갈이군에서 더욱 현저하게 관찰되었다. 이 실험의 결과는 이갈이는 BTX-A 주사 후에 발생한 교근 위축과 교합력 감소가 원상태로 회복되는 과정에 영향을 미칠 수 있음을 보여준다. 그러므로 이갈이 등의 이상기능 습관을 가진 교근비대 환자의 BTX-A 주사효과를 보다 오래 유지하기 위해서 주사와 함께 습관조절을 위한 교합장치의 사용을 고려할 필요가 있을 것으로 생각된다.
This study aimed to evaluate a relation of bruxism with clinical effects of botulinum toxin type A(BTX-A) injection. 5 bruxers and 5 nonbruxers with bilateral masseter hypertrophy were participated in this study. After injecting 25 unit of BTX-A(Allergen Inc, $Botox^{(R)}$) into each mass...
This study aimed to evaluate a relation of bruxism with clinical effects of botulinum toxin type A(BTX-A) injection. 5 bruxers and 5 nonbruxers with bilateral masseter hypertrophy were participated in this study. After injecting 25 unit of BTX-A(Allergen Inc, $Botox^{(R)}$) into each masseter muscle, the thickness of masseter(Mm) and anterior temporalis(Ta) muscles was measured by ultrasonography and the maximum bite force was evaluated during a 9-month period. Self-estimation on the recovery of occlusal force during mastication was done as well. Regardless of presence of bruxsim, all subjects showed significantly reduced Ms thickness(p<0.001) and maximum bite force at $1^{st}$ molars(p=0.027) with their peak at 3 months after injection, which then started to return. No significant difference was observed in Ta thickness and the bite force at the central incisors. While self-estimated occlusal force was the least at 2 weeks after injection and then rapidly returned to the baseline level with full recovery at the time of 6 to 9 months after injection, the maximum bite force measured by bite force recorder did not recover the original value, particularly in the nonbruxer group. It is assumed that nocturnal bruxism can influence recovery of atrophic masseter and decreased occlusal force due to BTX-A injection. These findings suggest a need of occlusal appliance to control bruxism or clenching habit for longer clinical effect of BTX-A injection.
This study aimed to evaluate a relation of bruxism with clinical effects of botulinum toxin type A(BTX-A) injection. 5 bruxers and 5 nonbruxers with bilateral masseter hypertrophy were participated in this study. After injecting 25 unit of BTX-A(Allergen Inc, $Botox^{(R)}$) into each masseter muscle, the thickness of masseter(Mm) and anterior temporalis(Ta) muscles was measured by ultrasonography and the maximum bite force was evaluated during a 9-month period. Self-estimation on the recovery of occlusal force during mastication was done as well. Regardless of presence of bruxsim, all subjects showed significantly reduced Ms thickness(p<0.001) and maximum bite force at $1^{st}$ molars(p=0.027) with their peak at 3 months after injection, which then started to return. No significant difference was observed in Ta thickness and the bite force at the central incisors. While self-estimated occlusal force was the least at 2 weeks after injection and then rapidly returned to the baseline level with full recovery at the time of 6 to 9 months after injection, the maximum bite force measured by bite force recorder did not recover the original value, particularly in the nonbruxer group. It is assumed that nocturnal bruxism can influence recovery of atrophic masseter and decreased occlusal force due to BTX-A injection. These findings suggest a need of occlusal appliance to control bruxism or clenching habit for longer clinical effect of BTX-A injection.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
문제 정의
This study aimed to investigate whether or not the presence of bruxism influences the treatment effect of BTX-A injection in the subjects with the masseteric muscle hypertrophy.
제안 방법
To investigate the changes in occlusal force of the subjects, the maximum bite force at each follow-up was measured at anterior and posterior teeth, separately by the bite force recorder. After placing the recorder between antagonizing 1st molars on the right side (posterior bite force) and being asked to bite lightly for several times in order to be familiar with the recorder, the subject was instructed to clench and increase the force successively to the maximal strength for five seconds. Rest period of 3 minutes was given to avoid muscle fatigue and then the same procedures were repeated on the left side.
Based on the presence of nocturnal bruxism, the subjects with bilateral masseteric hypertrophy were categorized into two groups; the bruxer and nonbruxer groups and their baseline data was compared by unpaired t-test(Table 1). It is noticeable that muscle thickness of Ta and Ms measured by ultrasonography was significantly greater in the bruxer group compared with the subjects without bruxing habit.
In addition to measurement with the bite force recorder, the subjects were instructed to self-estimate the changes of bite force during mastication following BTX-A injection using percentage value. 100% was defined as baseline level before BTX-A treatment.
2 years). Questionnaires to identify bruxers consisted of 4 questions about self-awareness of bruxism during sleep, report from bed partner, headache and/or stiffened jaws on awakening. None of them had serious medical problem including pregnancy and history of drug allergy and dental problems (i.
The transducer was held against the skin with a light pressure and oriented perpendicular to direction of the muscle fibers and underlying bone. Scans were made under relaxed(by asking the subject to maintain slight interocclusal contact) and maximum clenching conditions before and 2 weeks, 4 weeks, 8 weeks, 3 months, 6 months and 9 months after BTX-A injections.
To investigate the changes in occlusal force of the subjects, the maximum bite force at each follow-up was measured at anterior and posterior teeth, separately by the bite force recorder. After placing the recorder between antagonizing 1st molars on the right side (posterior bite force) and being asked to bite lightly for several times in order to be familiar with the recorder, the subject was instructed to clench and increase the force successively to the maximal strength for five seconds.
대상 데이터
10 healthy volunteers with bilateral masseter hypertrophy were selected for this study. 5 of them, proven to have nocturnal bruxism through self-reported questionnaires and clinical examination including assessment of occlusal wear, were categorized as the bruxer group(aged 26.
데이터처리
To compare baseline data between the bruxer and nonbruxer groups, unpaired t-test was used. Repeated measures two-way ANOVA was performed to investigate time-related changes of the muscle thickness and occlusal force after BTX-A injection. Significance level was determined at p<0.
To compare baseline data between the bruxer and nonbruxer groups, unpaired t-test was used. Repeated measures two-way ANOVA was performed to investigate time-related changes of the muscle thickness and occlusal force after BTX-A injection.
성능/효과
According to the results of this study, it is indicated that bruxism can influence the recovery of atrophic masseter and reduced occlusal force due to BTX-A injection, suggesting a need of occlusal appliance to control bruxism for longer clinical effect of BTX-A injection.
후속연구
A further study in a larger sample is required to demonstrate more definitely the effect of parafunctional habits on treatment outcome of BTX-A injection and quantitative measures for severity of bruxism is also needed.
참고문헌 (26)
Legg JW. Enlargement of the temporal and masseter muscles on both sides. Trans Pathol Soc Lond 1880;31:361-366
To EWH, Ahuja AT, Ho WS et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertro-phy with ultrasonographic and electromyographic measurement. Br J Plast Surg 2001;54:197-200
Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg 1994;32:25-28
von Lindern JJ, Niederhagen B, Appel T, Berge S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg 2001;107:327-332
Seligman DA, Pullinger AG, Solberg WK. The prevalence of dental attrition and its association with factors of age, gender, occlusion and TMJ symptomatology. J Dent Res 1988;67:1323-1333
Bowley JF, Stockstill JW, Pierece CJ. Reliability and validity of instrumentational used to record nocturnal clenching and/or grinding. J Orofac Pain 1993;7:378-385
Rivera-Morales WC, McCall WD Jr. Reliability of a portable electromyographic unit to measure bruxism. J Prosthet Dent 1995;73:184-189
Gallo LM, Lavigne G, Rompre P, Palla S. Reliabililty of scoring EMG orofacial events: polysomnography compared with ambulatory recordings. Journal of Sleep Research 1997; 6:259-263
Raadsheer MC, Van Eijden TMGJ, Van Spronsen PH et al. A comparison of human masseter muscle thickness measured by ultrasonography and magnetic resonance imaging. Archs Oral Biol 1994;39: 1079-1084
Jang HY, Kang SC, Kim ST, Kim CY, Choi JH. Effect of botulinum toxin type A and occlusal splint on masseter muscle evaluated with computed tomographic measurement. Korean J Oral Med 2005;30:247-255
Kim HS, Kim KS, Kim ST, Choi JH. Influence of botulinum toxin A injection on the electromyographic activity of masseter muscle. Korean J Oral Med 2004;29:435-444
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.